
Global Neurological Disorder Drugs Market Growth (Status and Outlook) 2025-2031
Description
According to this study, the global Neurological Disorder Drugs market size will reach US$ 4071 million by 2031.
Several government initiatives across various countries to educate masses about the rise of various diseases and increasing healthcare sector producing new drugs are the prime reasons for growth of neurological disorder drugs market. European Parkinson’s Disease Association, in Europe is actively supporting research and development by campaigning to raise awareness, and providing medication to patients is boosting the overall neurological disorder drugs market. This region is also witnessing rising focus on research and development programs that will help in producing affordable and effective drugs. The countries are collectively spending on developing neurological disorder drugs thus, improving the revenue of the market during the forecast period.
Staggering increase in brain altering disorders such as Alzheimer’s, epilepsy, Parkinson’s, cerebrovascular, and sclerosis are promoting the pharmaceutical firms to tap into the significantly growing neurological disorder drugs market. This will potentially supplement the market growth in the coming years. Rise of several innovative drugs to manage these diseases will swell up the investments in the market. Increasing number of clinical trials are another reason boosting the market. Rise in geriatric population along with patients with strokes, migraines, and headaches leading to cerebrovascular diseases are likely to augment the growth of the market.
LPI (LP Information)' newest research report, the “Neurological Disorder Drugs Industry Forecast” looks at past sales and reviews total world Neurological Disorder Drugs sales in 2024, providing a comprehensive analysis by region and market sector of projected Neurological Disorder Drugs sales for 2025 through 2031. With Neurological Disorder Drugs sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Neurological Disorder Drugs industry.
This Insight Report provides a comprehensive analysis of the global Neurological Disorder Drugs landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on Neurological Disorder Drugs portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Neurological Disorder Drugs market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Neurological Disorder Drugs and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Neurological Disorder Drugs.
This report presents a comprehensive overview, market shares, and growth opportunities of Neurological Disorder Drugs market by product type, application, key players and key regions and countries.
Segmentation by Type:
Antipsychotic
Hypnotic & Sedative
Analgesics
Anticoagulants
Others
Segmentation by Application:
Hospital
Clinic
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Novartis
GlaxoSmithKline
Merck & Co.
Bayer
AstraZeneca
Boehringer Ingelheim
Teva Pharmaceutical
Please note: The report will take approximately 2 business days to prepare and deliver.
Several government initiatives across various countries to educate masses about the rise of various diseases and increasing healthcare sector producing new drugs are the prime reasons for growth of neurological disorder drugs market. European Parkinson’s Disease Association, in Europe is actively supporting research and development by campaigning to raise awareness, and providing medication to patients is boosting the overall neurological disorder drugs market. This region is also witnessing rising focus on research and development programs that will help in producing affordable and effective drugs. The countries are collectively spending on developing neurological disorder drugs thus, improving the revenue of the market during the forecast period.
Staggering increase in brain altering disorders such as Alzheimer’s, epilepsy, Parkinson’s, cerebrovascular, and sclerosis are promoting the pharmaceutical firms to tap into the significantly growing neurological disorder drugs market. This will potentially supplement the market growth in the coming years. Rise of several innovative drugs to manage these diseases will swell up the investments in the market. Increasing number of clinical trials are another reason boosting the market. Rise in geriatric population along with patients with strokes, migraines, and headaches leading to cerebrovascular diseases are likely to augment the growth of the market.
LPI (LP Information)' newest research report, the “Neurological Disorder Drugs Industry Forecast” looks at past sales and reviews total world Neurological Disorder Drugs sales in 2024, providing a comprehensive analysis by region and market sector of projected Neurological Disorder Drugs sales for 2025 through 2031. With Neurological Disorder Drugs sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Neurological Disorder Drugs industry.
This Insight Report provides a comprehensive analysis of the global Neurological Disorder Drugs landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on Neurological Disorder Drugs portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Neurological Disorder Drugs market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Neurological Disorder Drugs and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Neurological Disorder Drugs.
This report presents a comprehensive overview, market shares, and growth opportunities of Neurological Disorder Drugs market by product type, application, key players and key regions and countries.
Segmentation by Type:
Antipsychotic
Hypnotic & Sedative
Analgesics
Anticoagulants
Others
Segmentation by Application:
Hospital
Clinic
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Novartis
GlaxoSmithKline
Merck & Co.
Bayer
AstraZeneca
Boehringer Ingelheim
Teva Pharmaceutical
Please note: The report will take approximately 2 business days to prepare and deliver.
Table of Contents
90 Pages
- *This is a tentative TOC and the final deliverable is subject to change.*
- 1 Scope of the Report
- 2 Executive Summary
- 3 Neurological Disorder Drugs Market Size by Player
- 4 Neurological Disorder Drugs by Region
- 5 Americas
- 6 APAC
- 7 Europe
- 8 Middle East & Africa
- 9 Market Drivers, Challenges and Trends
- 10 Global Neurological Disorder Drugs Market Forecast
- 11 Key Players Analysis
- 12 Research Findings and Conclusion
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.